[Retracted] Facial Nerve Monitoring under Different Levels of Neuromuscular Blockade with Cisatracurium Besilate in Parotid Tumour Surgery

Abstract

Background. Anaesthesia can alter neuronal excitability and vascular reactivity and ultimately lead to neurovascular coupling. Precise control of the skeletal muscle relaxant doses is the key in reducing anaesthetic damage. Methods. A total of 102 patients with the normal functioning preoperative facial nerve who required parotid tumour resection were included in this study. Facial nerve monitoring was conducted intraoperatively. The surgeon stimulated the facial nerve at different myorelaxation intervals at TOF% (T4/T1) and T1% (T1/T0) and recorded the responses and the amplitude of electromyogram (EMG). Body movements (BM) or patient-ventilator asynchrony (PVA) was recorded intraoperatively. Results. In parotid tumour resection, T1% should be maintained at a range of 30 to 60% while TOF% should be maintained at a range of 20 to 30%. Analysis of the decision tree model for facial nerve monitoring suggests a partial muscle relaxation level of 30 % < T 1 % ≤ 50 % and TOF ≤ 60 % . A nomogram prediction model, while incorporating factors such as sex, age, BMI, TOF%, and T1%, was constructed to predict the risk of BM/PVA during surgery, showing good predictive performance. Conclusions. This study revealed an adequate level of neuromuscular blockade in intraoperative parotid tumour resection while conducting facial nerve monitoring. A visual nomogram prediction model was constructed to guide anaesthetists in improving the anaesthetic plan.

Machine learning for infection risk prediction in postoperative patients with non-mechanical ventilation and intravenous neurotargeted drugs

“…The development of clinical drugs used for analgesia and sedation of ICU patients has been increasing in number. Assessing the condition and determining its pharmacology can lead to better analgesia with narcotics (6)(7)(8)(9). In the ICU, we are more likely to make better treatment decisions if we understand the different effects of anesthesia on the neurovascular system (10).…”

Antagonist of Chrna1 prevents the pathogenesis of primary focal hyperhidrosis

“…Our previous study suggested that the increased expression of Chrna1 is an important cause of excessive sweat secretion, and the use of small molecules to block the activity of Chrna1 may be an effective method for the treatment of PFH. Cisatracurium has been reported to inhibit Chrna1, 13 and it has been used clinically as a skeletal muscle relaxant in many situations 14–16 . Therefore, we sought to investigate the effect of cisatracurium in PFH and possible mechanisms in an animal model of PFH.…”

“…Cisatracurium has been reported to inhibit Chrna1, 13 and it has been used clinically as a skeletal muscle relaxant in many situations. 14 , 15 , 16 Therefore, we sought to investigate the effect of cisatracurium in PFH and possible mechanisms in an animal model of PFH.…”

Alzheimer's disease-associated inflammatory pathways might contribute to osteoporosis through the interaction between PROK2 and CSF3

“…With the advancement in bioinformatics and highthroughput sequencing, it is now possible to screen the differentially expressed genes (DEGs) using microarray gene expression profiling (19)(20)(21)(22)(23). Publicly available databases and repositories that store information on gene expression, microarrays, and clinical samples can help understand the underlying mechanism of the disease and screen potential molecular targets quickly and efficiently before their use in clinical settings (24)(25)(26).…”